BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46

Benzinga Newsdesk www.benzinga.com Positive 56.1%

Neg 0% Neu 0% Pos 56.1%

BMO Capital analyst Malcolm Hoffman initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $46.